Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B, HKEX: 03378) disclosed a Next Day Disclosure Return showing a fresh share buy-back executed on 14 May 2026.

The company repurchased 27,800 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 29.46 to HKD 32.00, with a volume-weighted average cost of HKD 30.16 per share. Total cash outlay reached approximately HKD 0.84 million. All repurchased shares have been retained as treasury stock.

Following the transaction, the number of issued shares (excluding treasury shares) fell from 135.62 million to 135.59 million, a marginal decline of 0.02%. Treasury shares increased to 0.63 million, while the total issued share count remained unchanged at 136.22 million.

Under the repurchase mandate approved on 12 February 2026, HANXBIO-B is authorised to buy back up to 13.62 million shares. Cumulative repurchases now stand at 626,400 shares, representing 0.46% of the issued share capital on the mandate date.

In accordance with Hong Kong listing rules, the company is restricted from issuing new shares or selling treasury shares until 13 June 2026. The board confirmed that all repurchases were executed in compliance with relevant regulations and that requisite procedural and filing requirements have been met.